

## CASE REPORTS

24. Meriwether WD, Mangi RJ, Serpick AA: Deafness following standard intravenous dose of ethacrynic acid. *JAMA* 216:795-798, 1971
25. Pillay VK, Schwartz FD, Aimi K, et al: Transient and permanent deafness following treatment with ethacrynic acid in renal failure. *Lancet* 1:77-79, Jan 11, 1969
26. Ng PS, Conley CE, Ing TS: Deafness after ethacrynic acid. *Lancet* 1:673-674, Mar 29, 1969
27. Quick CA, Hoppe W: Permanent deafness associated with furosemide administration. *Ann Otol* 84:94-101, 1975
28. Schneider WJ, Becker EL: Acute transient hearing loss after ethacrynic acid therapy. *Arch Intern Med* 117:715-717, 1966
29. Schwartz GH, David DS, Riggio RR, et al: Ototoxicity induced by furosemide. *N Engl J Med* 282:1413-1414, 1970
30. Vargish T, Benjamin R, Shenkman L: Deafness from furosemide. *Ann Intern Med* 72:761, 1970
31. Venkateswaran PS: Transient deafness from high doses of furosemide. *Br Med J* 4:113-114, 1971
32. Jackson GG, Arcieri G: Ototoxicity of gentamicin in man. *J Inf Dis* 124(Suppl):130-137, 1971
33. Narango CA, Bustos U, Cassis L: Furosemide-induced adverse reactions during hospitalization. *Am J Hosp Pharm* 35:794-798, 1978
34. Greenblatt DJ, Duhme DW, Allen MD, et al: Clinical toxicity of furosemide in hospitalized patients. *Am Heart J* 94:6-13, 1977
35. Miller RR, Greenblatt DJ (Ed): *Drug Effects in Hospitalized Patients*. New York, John Wiley and Sons, 1976, pp 86-90
36. Wigand ME, Heidland A: Ototoxic side effects of high doses of furosemide in patients with uremia. *Postgrad Med J* 47:(Apr Suppl)54-56, 1971
37. Huang CM, Atkinson AJ, Levin M, et al: Pharmacokinetics of furosemide in advanced renal failure. *Clin Pharm Ther* 16:659-666, 1974
38. Cooperman LB, Rubin IL: Toxicity of ethacrynic acid and furosemide. *Am Heart J* 85:831-834, 1973
39. Boston Collaborative Drug Surveillance Program: Drug-induced deafness. *JAMA* 224:515-516, 1973
40. Matz GJ, Beal DD, Krames L: Ototoxicity of ethacrynic acid demonstrated in a human temporal bone. *Arch Otolaryngol* 90:152-155, 1969
41. Cohn ES, Gordis EH, Brusilow SW: Ethacrynic acid effect on the composition of cochlear fluids. *Science* 171:910-911, 1971
42. Schwartz FD, Pillay VK, Karla RM: Ethacrynic acid: Its usefulness and untoward effects. *Am Heart J* 79:427-428, 1970
43. Martindale: *The Extra Pharmacopoeia*, 27th Ed. London, The Pharmaceutical Press, 1977, pp 552-559
44. Schmidt P, Friedman IS: Adverse effects of ethacrynic acid. *NY State J Med* 67:1438-1442, 1967
45. Patak RV, Lifschitz MD, Stein JH: Acute renal failure: Clinical aspects and pathophysiology. *Cardiovas Med* 4:19-38, 1979
46. Stein JH, Lifschitz MD, Barnes LD: Current concepts on the pathophysiology of acute renal failure. *Am J Physiol* 234(3):F171-F181, 1978
47. Muth RG: Furosemide in acute renal failure. In Friedman EA, Eliahou HE (Eds): *Proceedings of the Conference on Acute Renal Failure*. Bethesda, NIH, DHEW Publ No 74-608, 1974, pp 245-263
48. Miller TR, Anderson RJ, Linas SL, et al: Urinary diagnostic indices in acute renal failure: A prospective study. *Ann Intern Med* 89:47-50, 1978
49. Chaffee WG: Hazards of ethacrynic acid. *JAMA* 212:159, 1970
50. Kleinknecht D, Ganeval D, Gonzalez-Duque LA, et al: Furosemide in acute oliguric renal failure: A controlled trial. *Nephron* 9:337-348, 1972
51. Epstein M, Schneider NS, Befeler B: Effect of intrarenal furosemide on renal function and intrarenal hemodynamics in acute renal failure. *Am J Med* 58:510-516, 1975
52. Zar JH: *Biostatistical Analysis*. Englewood Cliffs, NJ, Prentice Hall, 1974, pp 291-295, 529-531
53. Anderson RJ, Linas SL, Berns AS, et al: Nonoliguric acute renal failure. *N Engl J Med* 296:1134-1138, 1977
54. Fleiss JL: *Statistical Methods for Rates and Proportions*. New York, John Wiley and Sons, 1973, pp 23-24

## Scientific Writing Award

THE JEAN SPENCER FELTON, MD, AWARD FOR EXCELLENCE IN SCIENTIFIC WRITING is given annually by the Western Occupational Medical Association to the author of a book, journal article or other written work important to the field of occupational health. Authors should reside in the western states, but need not belong to any particular organization. Presentation of the award will be made October 17, 1980.

Nominations should be accompanied by a copy of the written work and mailed by September 8, 1980, to Joseph LaDou, MD, Chairman, Jean Spencer Felton, MD, Award Committee, 1197 East Arques Avenue, Sunnyvale, CA 94086.